Drugs / Allogeneic Neonatal mesenchymal stromal cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06464588 | Jul 2025 → Jul 2027 expected | dilated cardiomyopathy | Emory University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Neonatal mesenchymal stromal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06464588 ↗ |
| Known as | nMSCs | “Allogeneic Neonatal mesenchymal stromal cells (nMSCs)” NCT06464588 ↗ |
| Modality | Cell therapy | “allogeneic neonatal mesenchymal stromal cells (nMSCs)” NCT06464588 ↗ |
| Route | Intravenous | “nMSCs will be administered intravenously” NCT06464588 ↗ |